Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses

Clinical Cancer Research

Volumn 22, Issue 5, 2016, Pages 1103-1110

  Sundaresan, Tilak K ^a,b   Sequist, Lecia V ^a,b   Heymach, John V ^c   Riely, Gregory J ^d   Jänne, Pasi A ^b,e   Koch, Walter H ^f   Sullivan, James P ^a,b   Fox, Douglas B ^a,b   Maher, Robert ^a,b   Muzikansky, Alona ^a   Webb, Andrew ^g   Tran, Hai T ^c   Giri, Uma ^c   Fleisher, Martin ^d   Yu, Helena A ^d   Wei, Wen ^f   Johnson, Bruce E ^b,e   Barber, Thomas A ^a   Walsh, John R ^a   Engelman, Jeffrey A ^a,b   Stott, Shannon L ^a,b   Kapur, Ravi ^a   Maheswaran, Shyamala ^a,b   Toner, Mehmet ^a,b   Haber, Daniel A ^a,b,h   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f ROCHE MOLECULAR SYSTEMS   (United States)

^g EKF Molecular Diagnostics   (United Kingdom)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; METHIONINE; THREONINE; AFATINIB; EGFR PROTEIN, HUMAN; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CELL POPULATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NON INVASIVE MEASUREMENT; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; TUMOR BIOPSY; BIOPSY; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GENOTYPE; MIDDLE AGED; MUTATION; PATHOLOGY; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84962222188     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1031     Document Type: Article

References (37)

1. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595-605.
2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
3. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
4. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31: 3327-34.
5. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
6. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7.
7. Kobayashi S, Boggon TJ, DayaramT, Janne PA, KocherO,MeyersonM, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
8. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
9. Engelman JA, Zejnullahu K,Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
10. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013;19:279-90.
11. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60.
12. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small cell lung cancer. N Engl J Med 2015;372:1700-9.
13. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer. N Engl J Med 2015;372:1689-99.
14. Network NCC. September 24, 2014. Non-small cell lung cancer (Version 4.2014). Available from: 〈http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf〈.
15. Piotrowska Z, Niederst M, Mino-Kenudson M, Morales V, Fulton L, Lockerman E, et al. Variation in mechanisms of acquired resistance among Egfr-mutant Nsclc patients with more than 1 post-resistant biopsy. Multidisciplinary Symposium in Thoracic Oncology. Volume 90. Chicago, Ilinois: International Journal of Radiation Oncology; 2014. p. S6-S7.
16. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
17. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone- chip. Proc Natl Acad Sci U S A 2010;107:18392-7.
18. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
19. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
20. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumorDNAas a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
21. Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS ONE 2014;9:e103883.
22. Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 2013;110:21083-8.
23. Pailler E, Adam J, Barthelemy A, Oulhen M, Auger N, Valent A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small cell lung cancer. J Clin Oncol 2013;31: 2273-81.
24. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
25. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
26. Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non- small cell lung cancer during treatment with erlotinib. Cancer 2014;120: 3896-901.
27. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-24.
28. Kim ES, Herbst RS,Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
29. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ,Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
30. Buttitta F, Felicioni L, DelGrammastro M, Filice G, Di Lorito A, Malatesta S, et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res 2013; 19:691-8.
31. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol 2013;66:1065-9.
32. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy.Clin Cancer Res 2015;21:3196-203.
33. Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 2015;7:1034-47.
34. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013;5:179ra47.
35. Graziano P, de Marinis F, Gori B, Gasbarra R, Migliorino R, De Santis S, et al. EGFR-driven behavior and intrapatient T790M mutation heterogeneity of non-small cell carcinoma with squamous histology. J Clin Oncol 2014;32:1-4.
36. Hata A, Masago K, Katakami N, Imai Y, Yatabe Y. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small cell lung cancer. J Thorac Oncol 2014;9:e64-5.
37. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-80.